PHAT
Price
$10.03
Change
+$0.99 (+10.95%)
Updated
Jun 12 closing price
Capitalization
700.24M
55 days until earnings call
PRME
Price
$1.46
Change
-$0.07 (-4.58%)
Updated
Jun 12 closing price
Capitalization
200.88M
54 days until earnings call
Interact to see
Advertisement

PHAT vs PRME

Header iconPHAT vs PRME Comparison
Open Charts PHAT vs PRMEBanner chart's image
Phathom Pharmaceuticals
Price$10.03
Change+$0.99 (+10.95%)
Volume$3.59M
Capitalization700.24M
Prime Medicine
Price$1.46
Change-$0.07 (-4.58%)
Volume$991.83K
Capitalization200.88M
PHAT vs PRME Comparison Chart
Loading...
PHAT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PRME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
PHAT vs. PRME commentary
Jun 13, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PHAT is a Buy and PRME is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 13, 2025
Stock price -- (PHAT: $10.03 vs. PRME: $1.46)
Brand notoriety: PHAT and PRME are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PHAT: 117% vs. PRME: 48%
Market capitalization -- PHAT: $700.24M vs. PRME: $200.88M
PHAT [@Biotechnology] is valued at $700.24M. PRME’s [@Biotechnology] market capitalization is $200.88M. The market cap for tickers in the [@Biotechnology] industry ranges from $352B to $0. The average market capitalization across the [@Biotechnology] industry is $2.45B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PHAT’s FA Score shows that 0 FA rating(s) are green whilePRME’s FA Score has 0 green FA rating(s).

  • PHAT’s FA Score: 0 green, 5 red.
  • PRME’s FA Score: 0 green, 5 red.
According to our system of comparison, PRME is a better buy in the long-term than PHAT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PHAT’s TA Score shows that 6 TA indicator(s) are bullish while PRME’s TA Score has 5 bullish TA indicator(s).

  • PHAT’s TA Score: 6 bullish, 4 bearish.
  • PRME’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, PHAT is a better buy in the short-term than PRME.

Price Growth

PHAT (@Biotechnology) experienced а +113.86% price change this week, while PRME (@Biotechnology) price change was +7.35% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.74%. For the same industry, the average monthly price growth was +15.53%, and the average quarterly price growth was +6.63%.

Reported Earning Dates

PHAT is expected to report earnings on Aug 07, 2025.

PRME is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (+4.74% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PHAT($700M) has a higher market cap than PRME($201M). PHAT YTD gains are higher at: 23.522 vs. PRME (-50.000). PRME has higher annual earnings (EBITDA): -200M vs. PHAT (-272.12M). PHAT has more cash in the bank: 212M vs. PRME (144M). PRME has less debt than PHAT: PRME (121M) vs PHAT (204M). PHAT has higher revenues than PRME: PHAT (81.9M) vs PRME (3.85M).
PHATPRMEPHAT / PRME
Capitalization700M201M348%
EBITDA-272.12M-200M136%
Gain YTD23.522-50.000-47%
P/E RatioN/AN/A-
Revenue81.9M3.85M2,129%
Total Cash212M144M147%
Total Debt204M121M169%
FUNDAMENTALS RATINGS
PRME: Fundamental Ratings
PRME
OUTLOOK RATING
1..100
3
VALUATION
overvalued / fair valued / undervalued
1..100
38
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
96
PRICE GROWTH RATING
1..100
64
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
PHATPRME
RSI
ODDS (%)
Bearish Trend 1 day ago
88%
N/A
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
89%
Momentum
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
83%
MACD
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 1 day ago
80%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
81%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
74%
Advances
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 7 days ago
77%
Declines
ODDS (%)
Bearish Trend 23 days ago
86%
Bearish Trend 1 day ago
89%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
79%
Bearish Trend 1 day ago
84%
View a ticker or compare two or three
Interact to see
Advertisement
PHAT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PRME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JETNX17.370.07
+0.40%
Janus Henderson Global Sust Eq N
LEIFX22.44N/A
N/A
Federated Hermes Equity Income A
IASCX11.59N/A
N/A
Voya Small Company Port A
SWMCX68.17N/A
N/A
Schwab ® US Mid-Cap Index
FTYCX42.57N/A
N/A
FullerThaler Behavioral Sm-Cp Eq C

PRME and

Correlation & Price change

A.I.dvisor indicates that over the last year, PRME has been loosely correlated with CRSP. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if PRME jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PRME
1D Price
Change %
PRME100%
-4.58%
CRSP - PRME
63%
Loosely correlated
-0.58%
BEAM - PRME
57%
Loosely correlated
-2.52%
RXRX - PRME
57%
Loosely correlated
-4.26%
CRBU - PRME
51%
Loosely correlated
-1.69%
IPSC - PRME
50%
Loosely correlated
-1.01%
More